JP2000505787A - 中皮抗原及びそれを標的化するための方法及びキット - Google Patents
中皮抗原及びそれを標的化するための方法及びキットInfo
- Publication number
- JP2000505787A JP2000505787A JP9525355A JP52535597A JP2000505787A JP 2000505787 A JP2000505787 A JP 2000505787A JP 9525355 A JP9525355 A JP 9525355A JP 52535597 A JP52535597 A JP 52535597A JP 2000505787 A JP2000505787 A JP 2000505787A
- Authority
- JP
- Japan
- Prior art keywords
- mesothelin
- polypeptide
- cells
- molecule
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.OVCAR-3及びHeLa細胞の細胞表面に結合される40KDのポリペプチド(K1 抗原)により十分に免疫吸着された、免疫原としての配列番号2の十分な長さの ポリペプチド(“メソセリン”)に対して生ぜしめられた抗血清に結合する、配 列番号2のポリペプチド配列からの少なくとも10個の隣接したアミノ酸のポリペ プチド抗原を担持する腫瘍細胞にエフェクター分子を特異的に供給するための方 法であって: メソセリンに特異的に結合する標的化分子に結合される前記エフェクター分子 を含んで成るキメラ分子を供給し;そして 前記腫瘍と、腫瘍細胞に特異的に結合する前記キメラ分子とを接触せしめるこ とを含んで成る方法。 2.前記標的化分子がメソセリンに対する抗体である請求の範囲第1項記載の 方法。 3.前記腫瘍が卵巣腫瘍細胞である請求の範囲第1項記載の方法。 4.前記エフェクター分子が、細胞毒素、ラベル、放射性核種、薬物、リポソ ーム、リガンド及び抗体から成る群から選択される請求の範囲第1項記載の方法 。 5.前記エフェクター分子が、プソイドモナス外毒素である請求の範囲第1項 記載の方法。 6.OVCAR-3及びHeLa細胞の細胞表面に結合される40KDのポリペプチド(K1 抗原)により十分に免疫吸着された、免疫原としての配列番号2の十分な長さの ポリペプチド(“メソセリン”)に対して生ぜしめられた抗血清に結合する、配 列番号2のポリペプチド配列からの少なくとも10個の隣接したアミノ酸のポリペ プチド抗原を 担持する腫瘍細胞の増殖を減じるための方法であって、 メソセリンを特異的に結合する標的化分子;及び 細胞毒素、放射性核種、リガンド及び抗体から成る群から選択されたエフェク ター分子を含んで成る、腫瘍細胞に特異的に結合するキメラ分子と、前記腫瘍と を接触せしめることを含んで成る方法。 7.前記細胞毒素が、プソイドモナス外毒素、リシン、アブリン、及びジフテ リア毒素から成る群から選択される請求の範囲第6項記載の方法。 8.前記腫瘍細胞増殖がヒトにおける腫瘍細胞増殖である請求の範囲第6項記 載の方法。 9.前記接触が、前記キメラ分子を、ヒト静脈内に、体腔中に、又は管腔もし くは器官中に投与することを含んで成る請求の範囲第6項記載の方法。 10.OVCAR-3及びHeLa細胞の細胞表面に結合される40KDのポリペプチド(K1 抗原)により十分に免疫吸着された、免疫原としての配列番号2の十分な長さの ポリペプチド(“メソセリン”)に対して生ぜしめられた抗血清に結合する、配 列番号2のポリペプチド配列からの少なくとも10個の隣接したアミノ酸のポリペ プチドを担持する腫瘍の存在又は不在を検出するための方法であって: メソセリンを特異的に結合する標的化分子;及び検出可能ラベルを含んで成る キメラ分子と前記腫瘍とを接触せしめ;そして前記ラベルの存在又は不在を検出 することを含んで成る方法。 11.医薬的に許容されるキャリヤー、及びOVCAR-3及びHeLa細胞の細胞表面に 結合される40KDのポリペプチド(K1抗原)により十分に免疫吸着された、免疫 原としての配列番号2の十分な長さのポリペプチドに対して生ぜしめられた抗血 清に結合する、配列番号2のポリペプチド配列からの少なくとも10個の隣接した アミノ酸のポ リペプチドに特異的に結合する標的化分子の治療的有効量を含んで成る薬理学的 組成物。 12.前記標的化分子が、キメラ分子を形成するためにエフェクター分子にさら に連結される請求の範囲第11項記載の薬理学的組成物。 13.前記エフェクター分子が、細胞毒素、ラベル、放射性核種、薬物、リポソ ーム、リガンド及び抗体から成る群から選択される請求の範囲第12項記載の組成 物。 14.前記キメラ分子が、一本鎖融合タンパク質である請求の範囲第12項記載の 組成物。 15.OVCAR-3及びHeLa細胞の細胞表面に結合される40KDのポリペプチド(K1 抗原)により十分に免疫吸着された、免疫原としての配列番号2の十分な長さの ポリペプチド(“メソセリン”)に対して生ぜしめられた抗血清に結合する、配 列番号2のポリペプチド配列からの少なくとも10個の隣接したアミノ酸のポリペ プチドに対して特異的な核酸又は抗体を有する容器、及びメソセリンを担持する 腫瘍細胞の検出のための使用説明書を含んで成る、メソセリンの検出のためのキ ット。 16.メソセリン発現又は活性の阻害のための方法であって、配列番号1に示さ れる核酸配列に対して特異的な阻害性核酸と、メソセリン担持の細胞とを接触せ しめることを含んで成る方法。 17.メソセリン由来の抗原を患者に投与することを含んで成る、中皮腫又は卵 巣腫瘍の阻害又は予防のためのワクチン。 18.メソセリンを担持する腫瘍細胞の処理のための薬物をスクリーニングする ための方法であって、配列番号1の配列に対して実質的に同一の核酸配列により トランスフェクトされた移植腫瘍細胞を含む哺乳類を、興味ある薬物にゆだね、 そして腫瘍細胞の活性をモ ニターすることを含んで成る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1016696P | 1996-01-05 | 1996-01-05 | |
US60/010,166 | 1996-01-05 | ||
PCT/US1997/000224 WO1997025068A2 (en) | 1996-01-05 | 1997-01-03 | Mesothelin antigen and methods and kits for targeting it |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007002808A Division JP2007197439A (ja) | 1996-01-05 | 2007-01-10 | 中皮抗原及びそれを標的化するための方法及びキット |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000505787A true JP2000505787A (ja) | 2000-05-16 |
Family
ID=21744267
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9525355A Withdrawn JP2000505787A (ja) | 1996-01-05 | 1997-01-03 | 中皮抗原及びそれを標的化するための方法及びキット |
JP2007002808A Pending JP2007197439A (ja) | 1996-01-05 | 2007-01-10 | 中皮抗原及びそれを標的化するための方法及びキット |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007002808A Pending JP2007197439A (ja) | 1996-01-05 | 2007-01-10 | 中皮抗原及びそれを標的化するための方法及びキット |
Country Status (9)
Country | Link |
---|---|
US (2) | US6083502A (ja) |
EP (1) | EP0871492B1 (ja) |
JP (2) | JP2000505787A (ja) |
AT (1) | ATE254931T1 (ja) |
AU (1) | AU703769B2 (ja) |
CA (1) | CA2241604C (ja) |
DE (1) | DE69726404T2 (ja) |
ES (1) | ES2212071T3 (ja) |
WO (1) | WO1997025068A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011504372A (ja) * | 2007-11-26 | 2011-02-10 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 抗メソセリン抗体およびその使用 |
JP2016026211A (ja) * | 2009-10-27 | 2016-02-12 | ユセベ ファルマ ソシエテ アノニム | 機能改変するNav1.7抗体 |
US10647779B2 (en) | 2009-04-29 | 2020-05-12 | Bayer Intellectual Property Gmbh | Anti-mesothelin immunoconjugates and uses therefor |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7314632B1 (en) * | 1997-07-11 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pseudomonas exotoxin A-like chimeric immunogens |
US20030054012A1 (en) * | 2000-05-12 | 2003-03-20 | Fitzgerald David J. | Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response |
ES2249838T3 (es) * | 1997-07-11 | 2006-04-01 | The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services | Inmunogenos quimericos similares a la exotoxina a de pseudomonas. |
US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
US6770445B1 (en) * | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
US7745159B2 (en) | 1999-02-26 | 2010-06-29 | Nathalie B Scholler | Methods and compositions for diagnosing carcinomas |
JP4813661B2 (ja) * | 1999-02-26 | 2011-11-09 | パシフィック ノースウエスト リサーチ インスティテュート | 癌を診断するための方法および組成物 |
DE60039510D1 (de) | 1999-05-27 | 2008-08-28 | Us Gov Health & Human Serv | Immunokonjugate mit hoher bindungsaffinität |
GB9924351D0 (en) | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
US6987024B1 (en) * | 2000-04-10 | 2006-01-17 | Raven Biotechnologies, Inc. | Human ovarian mesothelial cells and methods of isolation and uses thereof |
AU2002338446A1 (en) * | 2001-01-23 | 2002-11-05 | University Of Rochester Medical Center | Methods of producing or identifying intrabodies in eukaryotic cells |
SI2371854T1 (sl) | 2001-03-09 | 2014-09-30 | Board Of Regents, The University Of Texas System Office Of The General Counsel | Induciranje imunosti tumorja z variantami beljakovine, ki se veĺ˝e na folat |
WO2004006837A2 (en) * | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20090110702A1 (en) * | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
CA2515298C (en) * | 2003-02-06 | 2014-04-08 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
MXPA05008342A (es) * | 2003-02-06 | 2006-02-28 | Cerus Corp | Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas. |
US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
US20040180387A1 (en) * | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
CA2534659A1 (en) * | 2003-08-05 | 2005-02-17 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
US7399793B2 (en) * | 2003-10-31 | 2008-07-15 | Basf Corporation | Coating composition curable with ultraviolet radiation |
EP1725249B1 (en) | 2003-11-06 | 2014-01-08 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20060014221A1 (en) * | 2004-01-21 | 2006-01-19 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma |
US20060014211A1 (en) * | 2004-01-21 | 2006-01-19 | Fujirebio Diagnostics, Inc. | Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity |
WO2005080431A2 (en) | 2004-02-12 | 2005-09-01 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
ES2386367T3 (es) | 2005-03-10 | 2012-08-17 | Morphotek, Inc. | Anticuerpos anti-mesotelina |
EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
US20070207171A1 (en) * | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
US7935804B2 (en) * | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
ES2532942T3 (es) | 2006-03-01 | 2015-04-06 | Aduro Biotech | Listeria obtenida por ingeniería genética y métodos de uso de la misma |
WO2008105814A2 (en) * | 2006-08-22 | 2008-09-04 | Los Alamos National Security, Llc | Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids |
US20090093019A1 (en) * | 2007-04-27 | 2009-04-09 | Phelps Jamie P | Production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
ES2579323T3 (es) | 2007-07-16 | 2016-08-09 | Genentech, Inc. | Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso |
PE20090481A1 (es) | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
JP2009028871A (ja) | 2007-07-30 | 2009-02-12 | Denso Wave Inc | ロボット制御装置 |
KR101554848B1 (ko) | 2007-10-01 | 2015-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
SI2657253T1 (sl) | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
EP2257572A1 (en) * | 2008-03-27 | 2010-12-08 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Human anti-mesothelin monoclonal antibodies |
US8785134B2 (en) * | 2008-11-10 | 2014-07-22 | The Mitre Corporation | Glycoprotein vesicles and their methods of use |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
AU2010292069B2 (en) | 2009-09-11 | 2015-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Improved Pseudomonas Exotoxin A with reduced immunogenicity |
WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
PH12018500046A1 (en) | 2010-12-20 | 2019-04-08 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
US10519492B2 (en) | 2011-04-20 | 2019-12-31 | Mesa Biotech, Inc. | Integrated device for nucleic acid detection and identification |
MX2013012905A (es) | 2011-05-06 | 2014-04-25 | Us Gov Health & Human Serv | Inmunotoxina recombinante dirigida a la mesotelina. |
AR087380A1 (es) * | 2011-07-27 | 2014-03-19 | Baylor Res Inst | Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas |
US9127081B2 (en) | 2012-05-10 | 2015-09-08 | Washington University | Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
AU2013306076B2 (en) | 2012-08-21 | 2018-01-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
EP2900695B1 (en) | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
WO2014182532A1 (en) | 2013-05-07 | 2014-11-13 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Mesothelin-specific immunocytokine and use thereof |
WO2016049214A1 (en) | 2014-09-23 | 2016-03-31 | Genentech, Inc. | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016196506A1 (en) | 2015-05-29 | 2016-12-08 | Galena Biopharma, Inc. | PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS |
EP3393504A1 (en) | 2015-12-22 | 2018-10-31 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
AU2016382512A1 (en) | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
TW202111125A (zh) | 2016-01-19 | 2021-03-16 | 美商輝瑞股份有限公司 | 癌症疫苗 |
SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
IL262321B1 (en) | 2016-04-15 | 2024-05-01 | Novartis Ag | Preparations and methods for selective protein expression |
EP3463438B1 (en) | 2016-05-31 | 2022-04-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine therapy for treatment of endometrial and ovarian cancer |
KR20190036551A (ko) | 2016-08-01 | 2019-04-04 | 노파르티스 아게 | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 |
GB201616699D0 (en) | 2016-09-30 | 2016-11-16 | Mab Designs Ltd | Antibodies |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
CN111683962A (zh) | 2017-11-10 | 2020-09-18 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
EP3897637A1 (en) | 2018-12-20 | 2021-10-27 | Novartis AG | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020146182A1 (en) | 2019-01-08 | 2020-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202135858A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 抗TGFβ抗體和檢查點抑制劑用於治療增殖性疾病之用途 |
IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | zbtb32 inhibitors and uses thereof |
AU2021297099A1 (en) | 2020-06-23 | 2023-01-05 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001629A1 (en) * | 1987-08-19 | 1989-02-23 | Centocor, Inc. | Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3 |
US5608039A (en) * | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
CA2093928C (en) * | 1990-10-12 | 2000-02-29 | Mark C. Willingham | Monoclonal antibodies for detection and treatment of cancer |
JP3328341B2 (ja) * | 1991-12-27 | 2002-09-24 | 中外製薬株式会社 | 新規な巨核球増幅因子 |
JP3490125B2 (ja) * | 1992-10-23 | 2004-01-26 | 中外製薬株式会社 | 巨核球増幅因子をコードする遺伝子 |
IL107366A (en) * | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
-
1997
- 1997-01-03 AU AU16927/97A patent/AU703769B2/en not_active Expired
- 1997-01-03 JP JP9525355A patent/JP2000505787A/ja not_active Withdrawn
- 1997-01-03 US US08/776,271 patent/US6083502A/en not_active Expired - Lifetime
- 1997-01-03 AT AT97902853T patent/ATE254931T1/de not_active IP Right Cessation
- 1997-01-03 CA CA2241604A patent/CA2241604C/en not_active Expired - Lifetime
- 1997-01-03 DE DE69726404T patent/DE69726404T2/de not_active Expired - Lifetime
- 1997-01-03 EP EP97902853A patent/EP0871492B1/en not_active Expired - Lifetime
- 1997-01-03 WO PCT/US1997/000224 patent/WO1997025068A2/en active IP Right Grant
- 1997-01-03 ES ES97902853T patent/ES2212071T3/es not_active Expired - Lifetime
-
1998
- 1998-12-17 US US09/215,035 patent/US6153430A/en not_active Expired - Lifetime
-
2007
- 2007-01-10 JP JP2007002808A patent/JP2007197439A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011504372A (ja) * | 2007-11-26 | 2011-02-10 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 抗メソセリン抗体およびその使用 |
JP2014221064A (ja) * | 2007-11-26 | 2014-11-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 抗メソセリン抗体およびその使用 |
JP2018102311A (ja) * | 2007-11-26 | 2018-07-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 抗メソセリン抗体およびその使用 |
US10647779B2 (en) | 2009-04-29 | 2020-05-12 | Bayer Intellectual Property Gmbh | Anti-mesothelin immunoconjugates and uses therefor |
US10781263B2 (en) | 2009-04-29 | 2020-09-22 | Bayer Intellectual Property Gmbh | Anti-mesothelin immunoconjugates and uses therefor |
JP2016026211A (ja) * | 2009-10-27 | 2016-02-12 | ユセベ ファルマ ソシエテ アノニム | 機能改変するNav1.7抗体 |
Also Published As
Publication number | Publication date |
---|---|
CA2241604C (en) | 2010-03-30 |
AU703769B2 (en) | 1999-04-01 |
AU1692797A (en) | 1997-08-01 |
JP2007197439A (ja) | 2007-08-09 |
US6153430A (en) | 2000-11-28 |
WO1997025068A3 (en) | 1997-10-23 |
EP0871492A2 (en) | 1998-10-21 |
WO1997025068A2 (en) | 1997-07-17 |
DE69726404D1 (de) | 2004-01-08 |
EP0871492B1 (en) | 2003-11-26 |
DE69726404T2 (de) | 2004-09-09 |
ATE254931T1 (de) | 2003-12-15 |
CA2241604A1 (en) | 1997-07-17 |
US6083502A (en) | 2000-07-04 |
ES2212071T3 (es) | 2004-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000505787A (ja) | 中皮抗原及びそれを標的化するための方法及びキット | |
US6689744B2 (en) | Notch receptor agonists and uses | |
JP3859695B2 (ja) | C―erbB―2外部ドメイン:GP75 | |
US7183388B2 (en) | Anti-MUC-1 single chain antibodies for tumor targeting | |
JP5328155B2 (ja) | Adam−9モジュレータ | |
CA2419270C (en) | Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof | |
CA2572451C (en) | Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature | |
JP2660241B2 (ja) | モノクロナール抗体 | |
JPH09511141A (ja) | 受容体Tieを認識するモノクローナル抗体およびそれらの用途 | |
US20030082188A1 (en) | Treatment of prostate cancer by inhibitors of NCAM2 | |
PL219043B1 (pl) | Kompozycja farmaceutyczna, kompozycja farmaceutyczna do zastosowania w leczeniu choroby, czynnik do zastosowania w sposobie diagnozowania, czynnik do zastosowania w sposobie oznaczania regresji, cytolityczne lub wydzielające cytokinę komórki T do zastosowania w sposobie leczenia, kwas nukleinowy, komórka gospodarza, polipeptyd, przeciwciało, produkt sprzęgania przeciwciała i zestaw do wykrywania ekspresji | |
US5879898A (en) | Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors | |
US20090280556A1 (en) | Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas, and Ovarian Cancers and Methods and Kits for Targeting the Antigen | |
JPH08506801A (ja) | Cd44エキソン6に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法 | |
CA2340721A1 (en) | Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor | |
WO2006068822A1 (en) | Notch receptor agonists and uses | |
US20030077676A1 (en) | Anti-MUC-1 single chain antibodies for tumor targeting | |
WO2000018783A9 (en) | Mammaglobin, a secreted mammary-specific breast cancer protein | |
JP4365583B2 (ja) | ノッチレセプターアゴニスト及び用途 | |
CA1286238C (en) | Anti-epiglycanin monoclonal antibodies | |
AU2004289821B2 (en) | Adenocarcinoma specific antibody SAM-6, and uses thereof | |
JP3268147B2 (ja) | モノクローナル抗体 | |
AU2002255982A1 (en) | Anti-MUC-1 single chain antibodies for tumor targeting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061227 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070405 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081125 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090319 |